<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04242849</url>
  </required_header>
  <id_info>
    <org_study_id>N/A-NI-AML-PI-007344</org_study_id>
    <nct_id>NCT04242849</nct_id>
  </id_info>
  <brief_title>IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up</brief_title>
  <official_title>IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Josep Carreras Leukaemia Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Josep Carreras Leukaemia Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a spanish series of AML patients it is intended to perform, at the moment of diagnosis,
      pyrosequencing of IDH1 and IDH2 genes. Taking into account the incidence of AML in the area,
      it is planed to study 100 patients per year.

      Among the cases with IDH1/2 mutations, targeted deep sequencing (TDS) of a panel covering
      coding regions of 40 myeloid related genes will be applied. With TDS, pyrosequencing results
      will be validated at the same time that prognosis value of co-mutated genes could be studied.
      Furthermore, with TDS, molecular architecture of IDH1 and IDH2 mutated cases might be better
      understood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2016</start_date>
  <completion_date type="Actual">January 16, 2020</completion_date>
  <primary_completion_date type="Actual">December 27, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of IDH1/2 mutation</measure>
    <time_frame>1 day</time_frame>
    <description>Detection of mutations in IDH1 and IDH2 genes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of co-mutations</measure>
    <time_frame>1 day</time_frame>
    <description>Screening of aditional mutations in those cases with IDH1/2 mutation</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">354</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>IDH1/2 mutated patients</arm_group_label>
    <description>Patients harboring mutations in IDH1 or IDH2 genes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without IDH1/2 mutations</arm_group_label>
    <description>Patients that donÂ´t present any mutation in IDH1/2 genes</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients &gt;18 years old with de novo acute myeloid leukemia (AML).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 years old with de novo acute myeloid leukemia will be included. All
             patients will be treated according to clinical routine.

        Exclusion Criteria:

          -  Patients not following the above criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

